{"classes":[{"categories":[{"measurements":[{"comment":"The median and upper limit of 95% CI was not estimate due to limited number of events","groupId":"OG000","lowerLimit":"19.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Overall Survival was defined as the time from first dose until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"MEDIAN","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Up to approximately 178 weeks","title":"Part 2 - Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}